Article Information
History
- January 25, 2020.
Article Versions
- You are currently viewing Version 1 of this article (January 25, 2020 - 09:54).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Clara Alcon1,
- Albert Manzano-Muñoz1,
- Estela Prada2,3,
- Jaume Mora2,3,
- Aroa Soriano4,
- Gabriela Guillén4,5,
- Josep Roma4,
- Josep Samitier1,6,7,
- Alberto Villanueva8,9 and
- Joan Montero1,*
- 1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
- 2Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
- 3Department of Haematology and Oncology, Hospital Sant Joan de Déu Barcelona, 08950 Esplugues de Llobregat, Spain
- 4Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
- 5Department of Surgery, Universitat Autònoma de Barcelona (UAB), 08193. Barcelona, Spain
- 6Department of Electronics and Biomedical Engineering, University of Barcelona (UB), 08028 Barcelona, Spain
- 7Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029 Madrid, Spain
- 8Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, 08907 l’Hospitalet del Llobregat, Barcelona, Spain
- 9Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 l’Hospitalet de Llobregat, Barcelona, Spain
- ↵*Correspondance to Joan Montero (jmontero{at}ibecbarcelona.eu), Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Phone: +34 934 039 956; Fax: +34 934 039 702